MedTrace Logo

Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab

NCT02909348 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2023-03-02

No results posted yet for this study

Summary

There is a new form of cancer treatment called immunotherapy which does not attack cancer directly but works on the immune system to make it more effective. This type of treatment may have side effects which are called autoimmune side effects and are caused by the immune system attacking the normal parts of the body. At the moment doctors cannot predict which patients may be at more risk of developing such autoimmune side effects and doctors also cannot predict which patients are more likely to benefit. This study will analyse blood samples from patients receiving immunotherapy to see if markers can be identified to help make such predictions.

Conditions

Interventions

DRUG

Pembrolizumab

3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • University College, London

    collaborator OTHER

  • Royal Free Hospital NHS Foundation Trust

    lead OTHER

Principal Investigators

  • David Chao, FRCP DPhil · Royal Free London NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02909348 on ClinicalTrials.gov